Gum kills cancer-linked oral bacteria, study finds

If you have ever wondered whether the bacteria living in your mouth could be doing more than causing bad breath or cavities, a new study gives that suspicion some real weight. Researchers tested a chewing gum built from a common bean and an antimicrobial peptide directly against saliva and oral-rinse samples from head and neck cancer patients, and the results suggest it can selectively strip out two bacteria strongly linked to that cancer, along with a cancer-associated virus, without touching the bacteria the mouth actually needs. The findings, published in Scientific Reports, are early and lab-based, but the selectivity is the part worth paying attention to.

Bean-derived gum eliminates cancer-linked oral bacteria in patient samples

A single one-hour treatment with an experimental chewing gum extract reduced two bacteria strongly associated with head and neck cancer by more than 99 percent in saliva and oral-rinse samples taken directly from cancer patients. The gum combines two ingredients: FRIL (Flt3 Receptor Interacting Lectin, a virus-trapping protein extracted from the lablab bean) and protegrin-1 (a naturally occurring antimicrobial peptide already evaluated in Phase III clinical trials for chemotherapy-related mouth sores). Researchers at the University of Pennsylvania School of Dental Medicine, led by Henry Daniell, tested the combination on 39 to 40 patient samples and measured a 4 to 6 log reduction, meaning the bacteria count dropped by a factor of 10,000 to 1,000,000, in the two target species (statistically significant at p < 0.0001).

HNSCC patients and the bacteria behind their cancer

The two bacteria targeted, Porphyromonas gingivalis (Pg, a bacterium already tied to gum disease) and Fusobacterium nucleatum (Fn, a bacterium that also shows up in colorectal tumors), are both implicated in head and neck squamous cell carcinoma (HNSCC), a cancer of the mouth and throat. In this study, cancer patients carried Pg at levels 1,000 times higher than non-cancer participants, and prior research covered in Infectious Agents and Cancer has shown the two bacteria act synergistically, each amplifying the other's tumor-promoting effects on oral cells. A narrative review of the mechanism describes how these bacteria trigger chronic inflammation, block tumor-suppressing genes, and help cancer cells evade the immune system. HNSCC itself is no small problem: global data cited in the study puts new oral cancer cases at roughly 890,000 a year, with about half of patients dying after treatment, making it the seventh leading cancer type worldwide by incidence and mortality.

Ex vivo testing directly on real cancer patient samples

This is what researchers call an ex vivo study, meaning the gum extract was mixed with saliva and oral-rinse samples collected from real patients in a lab dish, not swallowed or chewed by the patients themselves. Samples came from head and neck cancer patients treated at the VA Greater Los Angeles Healthcare System and the University of Kansas Medical Center, then processed at Penn. Bacterial counts were measured the old-fashioned way, by growing the bacteria on selective culture plates and counting live colonies, rather than relying on DNA sequencing, which cannot distinguish living bacteria from dead genetic debris. The team also tested the gum against human papillomavirus (HPV), the virus responsible for a large share of oropharyngeal cancers, using an antibody-based assay. A single dose of the bean-gum extract alone (without protegrin-1) cut HPV viral load in saliva samples by 86 to 95 percent and aggregated the virus in 13 of 14 patient saliva samples tested.

What this could mean if it holds up in people

Nothing here means a stick of gum can treat cancer today; this is a laboratory test of extracted gum compounds against banked patient samples, not a treatment given to living patients. What is notable is the selectivity: while Pg and Fn were nearly eliminated, Streptococcus species, generally protective bacteria that help keep the oral microbiome balanced, were barely affected, dropping only 1 to 2 logs or not at all. The researchers attribute that survival to a protective outer capsule Streptococcus carries that Pg and Fn lack. For a reader concerned about oral cancer risk, the more actionable takeaway right now is the established one: current understanding links elevated Pg, Fn, and HPV in the mouth to HNSCC risk, and it is reasonable to ask a dentist or doctor about periodontal health and HPV vaccination status, standard, proven measures, rather than about a gum product that has not been tested in a clinical trial.

Small ex vivo sample, no living clinical trial yet

The authors are explicit about the limits of what they showed. This is an ex vivo study, and the paper states plainly that it "is not a human clinical study to monitor long-term changes in oral microbiome." Sample sizes, while meaningful for lab work, are modest: 14 to 40 patients per bacterial or viral measure, and 39 to 40 samples for the bacterial kill data. The gum also had no meaningful effect on the fungus Candida albicans or on Streptococcus, meaning it is not a universal oral antimicrobial, it appears targeted to a specific set of pathogens. And because HPV testing here used an antibody assay that detects viral surface protein rather than a method that confirms whether the virus is still infectious after treatment, the true clinical impact on transmission is not yet established.

Clinical trials and tumor-cell studies are the next step

The same chewing-gum manufacturing platform (built by Per Os Biosciences) already has an FDA-approved investigational new drug application for a related use, evaluating a different antiviral version of the gum for coronavirus infection and transmission in a registered trial (NCT05433181), which shows the delivery technology itself has cleared a regulatory bar for human testing, though for a different application. The researchers say their next steps are to test whether FRIL and protegrin-1 can penetrate actual tumor cells (since both HPV and the two bacteria can hide and persist inside cancer cells, not just on the surface) and to move toward a clinical trial that tracks the oral microbiome over time in living patients rather than banked samples. No timeline for a cancer-specific human trial was given in the paper.

Common Questions

Is this chewing gum available to buy or use? No. This is an experimental compound tested against patient samples in a lab, not an approved product or supplement, and it has not been tested as a treatment in living patients for cancer prevention.

Does this mean bad oral bacteria cause cancer? The study does not prove causation. It shows that two bacteria, Pg and Fn, are found at much higher levels in the mouths of head and neck cancer patients, and that other research has documented how these bacteria could plausibly promote tumor growth, but this study itself was designed to test a treatment, not to establish cause and effect.

Why does the gum kill some bacteria and not others? The researchers found that Streptococcus, a generally beneficial bacterial group, is protected by an outer capsule that Pg and Fn lack, which appears to explain why the treatment spared it while eliminating the two cancer-associated species.

What is FRIL and why does it come from a bean? FRIL (Flt3 Receptor Interacting Lectin) is a protein naturally found in the lablab bean that binds to sugar structures on virus surfaces, clumping viral particles together so they cannot infect cells. Because it can be produced in plants, the authors note it costs far less to manufacture than lab-synthesized alternatives.

References

1. Henry Daniell, Geetanjali Wakade, Rahul Singh, et al. (2026). Ex vivo HNSCC clinical studies using saliva and antiviral or antibacterial chewing gums reveal reduction in carcinogenic microbes. Scientific Reports. https://doi.org/10.1038/s41598-026-39062-w
2. Xiao Song, Jingfei Wang, Zhen Gu, et al. (2025). Porphyromonas gingivalis and Fusobacterium nucleatum synergistically strengthen the effect of promoting oral squamous cell carcinoma progression. Infectious Agents and Cancer. https://doi.org/10.1186/s13027-025-00689-5
3. Bing Wang, Juan Deng, Valentina Donati, et al. (2024). The Roles and Interactions of Porphyromonas gingivalis and Fusobacterium nucleatum in Oral and Gastrointestinal Carcinogenesis: A Narrative Review. Pathogens. https://doi.org/10.3390/pathogens13010093
4. Registered clinical trial for the antiviral chewing gum platform (coronavirus indication). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT05433181